Effects of salicylate on chondrocytes from osteoarthritic and contralateral knees of dogs with unilateral anterior cruciate ligament transection

Molecular pathogenesis of OA pain: Past, present, and future

OBJECTIVE

To provide a historical perspective and narrative review on research into the molecular pathogenesis of osteoarthritis pain.

DESIGN

PubMed databases were searched for combinations of "osteoarthritis", "pain" and "animal models" for papers that represented key phases in the history of osteoarthritis pain discovery research including epidemiology, pathology, imaging, preclinical modeling and clinical trials.

RESULTS

The possible anatomical sources of osteoarthritis pain were identified over 50 years ago, but relatively slow progress has been made in understanding the apparent disconnect between structural changes captured by radiography and symptom severity. Translationally relevant animal models of osteoarthritis have aided in our understanding of the structural and molecular drivers of osteoarthritis pain, including molecules such as nerve growth factor and C-C motif chemokine ligand 2. Events leading to persistent osteoarthritis pain appear to involve a two-step process involving changes in joint innervation, including neo-innervation of the articular cartilage, as well as sensitization at the level of the joint, dorsal root ganglion and central nervous system.

CONCLUSIONS

There remains a great need for the development of treatments to reduce osteoarthritis pain in patients. Harnessing all that we have learned over the past several decades is helping us to appreciate the important interaction between structural disease and pain, and this is likely to facilitate development of new disease modifying therapies in the future.

Chronic pain: osteoarthritis and cancer

Osteoarthritis and cancer pain are two types of chronic pain commonly seen in small animal practice. The management of osteoarthritic pain consists of both pharmacologic therapy and nonpharmacologic strategies, including exercise control, dietary management and surgical therapy. Nonsteroidal antiinflammatory drugs are commonly used, although there is still controversy about their effect on the underlying pathologic processes of osteoarthritis. Despite a lack of well-designed clinical trials, chondroprotective drugs and neutraceuticals have gained popularity. Cancer pain can result from direct tumor invasion, paraneoplastic syndromes or diagnostic and therapeutic procedures, including surgery, chemotherapy and radiation. Treatment of cancer pain consists of definitive or palliative therapy and management of therapy induced pain. Analgesic therapy should be based on the World Health Organization's three step analgesic ladder for the administration of analgesia to cancer patients.

Effect of 6-Methoxy-2-Naphthylacetic Acid (6MNA), the Active Metabolite of Nabumetone, on the Glycosaminoglycan Synthesis of Canine Articular Cartilage In Vitro : Comparison with Other Nonsteroidal Anti-Inflammatory Drugs

6-methoxy-2-naphthylacetic acid (6MNA), the active metabolite of nabumetone, a novel nonacidic NSAID, has been studied in an in vitro culture system to determine its effects on glycosaminoglycan synthesis of normal and osteoarthritic canine articular cartilage. The effects were contrasted with those of several other NSAIDs. Dexamethasone potently inhibited synthesis and was used as a positive control in these studies. To reduce the influence of protein binding with these drugs, experiments were performed both in the presence and in the absence of serum in the culture medium. At and above concentrations achieved in the plasma of nabumetone-treated patients, 6MNA did not inhibit glycosaminoglycan synthesis of normal or osteoarthritic cartilage. In contrast, some other NSAIDs had the propensity to significantly suppress chondrocyte synthetic activity.

In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage

Naproxen is a nonsteroidal anti-inflammatory drug commonly used in the clinical treatment of joint disease. In this study, its effect in vivo on the biochemical composition, metabolic activities, and metalloproteinase activities of normal canine articular cartilage was analyzed. The articular cartilage from the knee joints of dogs who had been given naproxen for 4 weeks to maintain a serum level of 40-50 micrograms/ml was examined. Control animals were given a placebo. Treatment with naproxen was not found to change the composition (water, collagen, and proteoglycan) of the articular cartilage. The culture studies of cartilage explants indicated that proteoglycan synthesis rates were unaffected by the treatment with naproxen but that proteoglycan release from the tissue was suppressed. Analysis of the cartilage for matrix metalloproteinase activities showed reduced activity of neutral matrix metalloproteinase by 80%, of collagenase by 40%, and of gelatinase by 87%, with no change in activity of acid metalloproteinase or of tissue inhibitor for metalloproteinase. These findings indicate that in vivo treatment with naproxen has the capacity to modulate catabolic activities in articular cartilage.

Increased release of matrix components from articular cartilage in experimental canine osteoarthritis

The release rates of specific components of the proteoglycan aggregates (G1 domain, the chondroitin sulfate and keratan sulfate containing portion of the protein core, and link protein) of the articular cartilage of mature beagles were studied at early stages of canine experimental osteoarthritis (OA), generated by transection of the anterior cruciate ligament. Analysis of cartilage explants and synovial fluids indicates that at early stages of experimental OA, there is increased release of the proteoglycan aggregates of the articular cartilage. This involves a release from the tissue of the components of the proteoglycan that are specifically involved with aggregation together with the glycosaminoglycans of the proteoglycan. These components were detected at elevated levels in the media of explants of cartilage from the operated joint, and in the synovial fluids of the operated joints.

Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage

The effects of tiaprofenic acid (TPA), a nonsteroidal antiinflammatory drug with high potency as a cyclooxygenase inhibitor, on the metabolism of normal and degenerating articular cartilage were examined. When present in the culture medium in clinically relevant concentrations encompassing those achieved in synovial fluid of patients treated with the drug, TPA had no significant effects on net proteoglycan synthesis in organ cultures of normal, osteoarthritic or atrophic canine articular cartilage. When fed to dogs for 8 weeks in a daily dose of 100 mg, TPA had no apparent effect on cartilage water content or uronic acid concentration. The suppression of net cartilage proteoglycan synthesis caused by immobilization was not affected by administration of TPA nor did the drug affect the proportion of newly synthesized glycosaminoglycans recovered from the spent culture medium, suggesting that it did not increase proteoglycan catabolism or affect the integrity of the cartilage matrix.